ST Pharm Co.,Ltd. (237690.KQ)
KRW 77400.0
(0.91%)
KRW 77400.0
(0.91%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 52.48 Billion KRW | 52.5% |
| 2022 | 39.7 Billion KRW | 77.33% |
| 2021 | 20.83 Billion KRW | 520.96% |
| 2020 | -2.11 Billion KRW | 69.4% |
| 2019 | -13.7 Billion KRW | -141.84% |
| 2018 | -6.41 Billion KRW | -108.74% |
| 2017 | 70.87 Billion KRW | -16.94% |
| 2016 | 92.52 Billion KRW | 117.48% |
| 2015 | 46.14 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 7.89 Billion KRW | -42.94% |
| 2024 Q2 | -3.06 Billion KRW | -39.49% |
| 2024 Q3 | 4.09 Billion KRW | -59.6% |
| 2023 Q2 | 7.32 Billion KRW | -18.13% |
| 2023 Q3 | 12.68 Billion KRW | 73.09% |
| 2023 Q4 | 27.53 Billion KRW | 117.08% |
| 2023 FY | - KRW | 52.5% |
| 2023 Q1 | 8.95 Billion KRW | -40.84% |
| 2022 Q1 | 4.26 Billion KRW | 36.6% |
| 2022 Q4 | 15.12 Billion KRW | 74.71% |
| 2022 FY | - KRW | 77.33% |
| 2022 Q3 | 8.65 Billion KRW | 17.08% |
| 2022 Q2 | 7.39 Billion KRW | 73.23% |
| 2021 Q4 | 3.12 Billion KRW | -72.6% |
| 2021 FY | - KRW | 520.96% |
| 2021 Q3 | 11.4 Billion KRW | 36.23% |
| 2021 Q2 | 8.37 Billion KRW | 382.68% |
| 2021 Q1 | -2.96 Billion KRW | -141.35% |
| 2020 Q2 | -1.44 Billion KRW | 75.68% |
| 2020 Q3 | -4.5 Billion KRW | -210.73% |
| 2020 Q4 | 7.16 Billion KRW | 259.07% |
| 2020 FY | - KRW | 69.4% |
| 2020 Q1 | -5.96 Billion KRW | 24.57% |
| 2019 Q4 | -7.9 Billion KRW | -1102.98% |
| 2019 Q2 | -1.68 Billion KRW | 68.11% |
| 2019 Q1 | -5.27 Billion KRW | 41.08% |
| 2019 FY | - KRW | -141.84% |
| 2019 Q3 | -656.81 Million KRW | 60.97% |
| 2018 Q1 | 2.34 Billion KRW | -86.09% |
| 2018 Q3 | -6.96 Billion KRW | -197.28% |
| 2018 FY | - KRW | -108.74% |
| 2018 Q2 | 7.15 Billion KRW | 205.38% |
| 2018 Q4 | -8.95 Billion KRW | -28.61% |
| 2017 Q4 | 16.85 Billion KRW | 29.0% |
| 2017 Q3 | 13.06 Billion KRW | -40.84% |
| 2017 FY | - KRW | -16.94% |
| 2017 Q2 | 22.08 Billion KRW | 3.24% |
| 2017 Q1 | 21.39 Billion KRW | 8.2% |
| 2016 Q4 | 19.77 Billion KRW | -16.21% |
| 2016 Q2 | 34.02 Billion KRW | 210.18% |
| 2016 FY | - KRW | 117.48% |
| 2016 Q1 | 10.97 Billion KRW | -15.62% |
| 2016 Q3 | 23.59 Billion KRW | -30.65% |
| 2015 Q3 | 19.16 Billion KRW | 217.42% |
| 2015 Q4 | 13 Billion KRW | -32.15% |
| 2015 Q2 | 6.03 Billion KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 6.54 Billion KRW | -701.48% |
| Hyundai Bioscience Co., Ltd. | -12.74 Billion KRW | 511.698% |
| ABL Bio Inc. | 2.1 Billion KRW | -2394.015% |
| Cellid, Co., Ltd. | -7.68 Billion KRW | 783.117% |